Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest China
DTG + 3TC demonstrated high virologic efficacy and good tolerability in patients with late presentation. However, the regimen may be associated with an increase in lipid levels and weight, highlighting the need for regular monitoring.
Authors
- Xiaoxin Xie
- Peng Jiao (ORCID: https://orcid.org/0000-0001-5348-6305)
- Hai Long (ORCID: https://orcid.org/0000-0001-5744-5623)
- Lin Gan
- Yanhua Fu
- Jun Li (ORCID: https://orcid.org/0000-0002-3637-1642)
- Shujing Ma
- Xiaoyan Yang (ORCID: https://orcid.org/0000-0003-3483-5658)
- Mei-Hua Wu
- Qing Wang (ORCID: https://orcid.org/0009-0004-6252-2565)
Institutions
- Guiyang Medical University (CN)
- Shanghai Public Health Clinical Center (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fmed.2025.1630960
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00